UnitedHealth Group is under criminal investigation for possible fraud and things get more complicated after the murder of its CEO by Luigi Mangione: WSJ

WASHINGTON-UnitedHealth Group, one of the largest health care providers in the United States, is currently under criminal investigation by the Department of Justice (DOJ) for possible Medicare fraud offenses. This investigation, overseen by the DOJ's healthcare fraud unit within the criminal division, has been ongoing since at least last summer. The investigation focuses on the company's Medicare Advantage business practices, which have come under scrutiny for possible fraudulent activity, reports The Wall Street Journal.

You may be interested in: Luigi Mangione pleads not guilty, prosecution seeks his death penalty

Details of the investigation

• Nature of the investigation: Although specific details are uncertain, the investigation focuses on possible criminal allegations related to UnitedHealth's Medicare Advantage operations. These practices involve the company receiving additional payments for covering sicker patients, which creates an incentive to document diagnoses that may not be completely accurate.
• Scope of Investigation: The DOJ's health fraud unit, known for pursuing overcharges and kickbacks in government health programs, has shifted its focus to insurers such as UnitedHealth that manage taxpayer-funded benefits for more than half of Medicare beneficiaries. The unit operates in more than a dozen cities, with prosecutors from the New York team charged with the investigation against UnitedHealth.
• Previous Investigations: This criminal investigation is part of a broader set of government investigations into UnitedHealth, including:
• • Civil investigations into Medicare billing practices at the company's physician offices.
  • Antitrust investigations for possible violations in the healthcare marketplace.

Impact on UnitedHealth

• Stock Performance: UnitedHealth's stock has experienced significant declines, falling nearly 50% in the last month. The company's stock price dropped more than 8% in after-market trading on May 14 following the Wall Street Journal's report on the investigation.
• Leadership change: Among these challenges, UnitedHealth recently replaced its CEO, Andrew Witty, with Stephen Hemsley, the company's president and former CEO. This unexpected change in leadership has further eroded investor confidence.
• Legal and regulatory pressures: The company also faces a shareholder lawsuit alleging that UnitedHealth lied to investors about negative business impacts following the murder of Brian Thompson, the CEO of UnitedHealth's insurance division, by Luigi Mangione.

Medicare advantage and fraud allegations

• Business model: Medicare Advantage plans allow private insurers to manage Medicare benefits for a fixed monthly fee. Insurers receive additional payments for covering sicker patients, which incentivizes documentation of more serious diagnoses to increase revenues.
• Alleged misconduct: Critics and whistleblowers have accused UnitedHealth of exaggerating patient diagnoses to increase profits. The Wall Street Journal report suggests that questionable UnitedHealth diagnoses may have added billions to taxpayer costs.
• Company Response: UnitedHealth denies these allegations, claiming that its analysis is "inaccurate and biased." The company maintains that Medicare Advantage provides better health outcomes and more affordable health care for millions of retirees compared to traditional Medicare.

Previous legal challenges

• Civil case: UnitedHealth faced a long-running civil Medicare fraud case that accused the company of overcharging the U.S. government by more than $2 billion. The company received a favorable ruling in March, moving closer to potential dismissal of the case.
• Internal whistleblower case: In an internal whistleblower case, a court-appointed magistrate recommended dismissing claims that UnitedHealth had submitted inaccurate diagnoses for collection. The DOJ is challenging this recommendation, and the final ruling has not yet been issued.

Broader Context

• Government scrutiny: The Trump administration and Congress are actively seeking to reduce federal healthcare spending, a critical source of success for UnitedHealth. The appointment of Mehmet Oz as head of Medicare and Medicaid has raised concerns about greater control over Medicare Advantage insurers.
• Public sentiment: The murder of Brian Thompson by Luigi Mangione, who some Americans saw as an exposé of high health care costs and the power of insurers to refuse certain treatments, has further complicated the company's image. Public officials condemned the killing, but the incident has highlighted broader problems in the healthcare industry.